Advanced Neurosciences Institute

Franklin, Tennessee 37064

0 studies enrolling now · 11 studies all time

What they study most

Central Neuropathic Pain, Hypogammaglobulinemia, Immunodeficiency, Infection, Bacterial, Multiple Sclerosis, Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting, Relapsing Remitting Multiple Sclerosis

Studies at this site

• Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis — Completed
• Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis — Completed
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis — Completed
• Immunodeficiency in MS — Status unconfirmed
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• A Cooperative Clinical Study of Abatacept in Multiple Sclerosis — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
• Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects — Status unconfirmed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed